Nuvalent, Inc.

About Nuvalent, Inc.

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precisely targeted therapies for cancer patients. The company designs small-molecule kinase inhibitors that overcome resistance and minimize off-target effects, addressing genetically defined tumors. Lead programs target ALK, ROS1, and other oncogenic drivers in non-small cell lung cancer and other solid tumors, with multiple candidates in Phase 1 and Phase 2 trials. Founded in 2017 and headquartered in Cambridge, Massachusetts, Nuvalent leverages structure-based drug design and deep genomic insights to advance next-generation precision oncology medicines.